港股異動 | 開拓藥業-B(9939.HK)升6%續創新高 福瑞他恩臨牀試驗首批患者成功入組給藥
格隆匯4月19日丨開拓藥業-B(9939.HK)拉昇漲5.98%,高見46.15港元再度刷新歷史新高價,年內已累計飆漲330%,總市值近170億港元。開拓藥業-B於2021年4月16日,福瑞他恩凝膠針對痤瘡適應症的臨牀試驗已於中國完成首批患者招募併成功給藥。針對雄激素脱髮適應症,福瑞他恩目前正在中國進行II期臨牀試驗。中國目前尚無有效的局部雄激素受體拮抗劑可用於痤瘡的治療,市場未被滿足的臨牀需求很大。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.